Company profile for Amolyt Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Amolyt Pharma is building on its team’s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.Amolyt Pharma’s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose meta...
Amolyt Pharma is building on its team’s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.Amolyt Pharma’s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
15, chemin du Saquin Espace Européen, Building G 69 130 Ecully
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/07/15/2912776/0/en/AstraZeneca-Closes-Acquisition-of-Amolyt-Pharma.html

GLOBENEWSWIRE
15 Jul 2024

https://www.globenewswire.com/news-release/2024/05/07/2876644/0/en/Amolyt-Pharma-Announces-Abstracts-Accepted-for-Presentation-at-the-GRS-Congress-ECE-and-ENDO.html

GLOBENEWSWIRE
07 May 2024

https://www.globenewswire.com/news-release/2024/05/02/2874145/0/en/Amolyt-Pharma-Granted-FDA-Fast-Track-Designation-for-Eneboparatide-for-the-Treatment-of-Hypoparathyroidism.html

GLOBENEWSWIRE
02 May 2024

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-buy-amolyt-pharma-105-bln-boost-rare-diseases-portfolio-2024-03-14/

REUTERS
15 Mar 2024

https://www.globenewswire.com//news-release/2023/11/16/2781765/0/en/Amolyt-Pharma-Named-Biotech-Company-of-the-Year-at-the-LSX-European-Lifestars-Awards.html

GLOBENEWSWIRE
16 Nov 2023

https://www.globenewswire.com//news-release/2023/10/16/2760578/0/en/Amolyt-Pharma-Announces-Data-on-Prevalence-of-Bone-Disease-in-Patients-with-Hypoparathyroidism-and-Favorable-Bone-Effects-of-Eneboparatide-at-the-American-Society-for-Bone-and-Mine.html

GLOBENEWSWIRE
16 Oct 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty